Log In
Print
BCIQ
Print
Print this Print this
 

TD139

  Manage Alerts
Collapse Summary General Information
Company Galecto Biotech AB
DescriptionGalectin-3 (LGALS3) inhibitor
Molecular Target Galectin-3 (LGALS3)
Mechanism of ActionGalectin-3 antagonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I/II
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$444.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today